NBIX
Neurocrine Biosciences Inc. Healthcare - Biotechnology Investor Relations →
Neurocrine Biosciences Inc. (NBIX) closed at $127.68 as of 2026-03-20, trading 5.3% above its 200-week moving average of $121.25. The stock is currently moving closer to the line, down from 7.2% last week. The 14-week RSI sits at 30, indicating neutral momentum.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.67 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 1508 weeks of data, NBIX has crossed below its 200-week moving average 17 times. On average, these episodes lasted 26 weeks. The average one-year return after crossing below was -5.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $12.8 billion, NBIX is a large-cap stock. The company generates a free cash flow yield of 3.1%. Return on equity stands at 16.4%, a solid level. The stock trades at 3.9x book value.
Share count has increased 3.7% over three years, indicating dilution. NBIX passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 29 years, a hypothetical investment of $100 in NBIX would have grown to $1634, compared to $1335 for the S&P 500. That represents an annualized return of 10.1% vs 9.3% for the index — confirming NBIX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 32.4% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: NBIX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After NBIX Crosses Below the Line?
Across 17 historical episodes, buying NBIX when it crossed below its 200-week moving average produced an average return of -0.2% after 12 months (median +1.0%), compared to +12.5% for the S&P 500 over the same periods. 59% of those episodes were profitable after one year. After 24 months, the average return was -18.5% vs +27.4% for the index.
Each line shows $100 invested at the moment NBIX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
NBIX has crossed below its 200-week MA 17 times with an average 1-year return of +-5.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 1997 | Sep 1997 | 20 | 20.7% | -2.4% | +1534.3% |
| Sep 1997 | Oct 1997 | 1 | 0.4% | -42.9% | +1226.5% |
| Oct 1997 | Nov 1999 | 106 | 51.0% | -27.6% | +1244.0% |
| Aug 2004 | Aug 2004 | 1 | 2.7% | +14.6% | +209.2% |
| Feb 2005 | Jul 2005 | 21 | 22.8% | +46.7% | +208.6% |
| Aug 2005 | Sep 2005 | 4 | 1.8% | -80.1% | +183.0% |
| Sep 2005 | Sep 2005 | 1 | 0.1% | -76.7% | +178.0% |
| May 2006 | Sep 2010 | 227 | 90.4% | -41.5% | +551.4% |
| May 2021 | May 2021 | 1 | 2.7% | -12.6% | +40.2% |
| May 2021 | Jun 2021 | 1 | 0.1% | +1.2% | +35.3% |
| Jul 2021 | Sep 2021 | 11 | 7.6% | +0.2% | +34.4% |
| Nov 2021 | Apr 2022 | 22 | 23.3% | +30.7% | +37.0% |
| Apr 2022 | Jun 2022 | 9 | 18.7% | +11.3% | +36.4% |
| Jul 2022 | Aug 2022 | 4 | 2.5% | -1.6% | +33.6% |
| Mar 2023 | Mar 2023 | 3 | 6.0% | +45.3% | +33.3% |
| May 2023 | Jul 2023 | 12 | 9.7% | +44.5% | +31.1% |
| Mar 2025 | May 2025 | 5 | 18.0% | N/A | +33.5% |
| Average | 26 | — | +-5.7% | — |
Frequently Asked Questions
Is NBIX below its 200-week moving average?
No. Neurocrine Biosciences Inc. (NBIX) is currently 5.3% above its 200-week moving average of $121.25. It would need to fall to $121.25 to cross below the line.
What is NBIX's 200-week moving average price?
Neurocrine Biosciences Inc.'s 200-week moving average is $121.25 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when NBIX drops below its 200-week moving average?
NBIX has crossed below its 200-week moving average 17 times in our data. The average one-year return after these crossings was -5.7%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 26 weeks on average.
Is NBIX a good value right now?
Here's what our data says about NBIX as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 30. Free cash flow yield is 3.1%. Return on equity is 16.4%. Price-to-book is 3.9x. This is not a buy or sell recommendation — always do your own research.
How does NBIX compare to the S&P 500?
Over the past 29 years, $100 invested in NBIX would have grown to $1634, compared to $1335 for the S&P 500. That's 10.1% annualized vs 9.3% for the index. NBIX has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20